Hengrui Medicine Investment Quality Review (600276.SH)

Data timestamp: 2026-08-07 22:07 UTC
Quality score: 64/100
Valuation position: current price / base fair value 3.31
Final signal: AVOID

Core View

Hengrui Medicine is a innovative and generic drugs company with a 64/100 quality score. The current signal is AVOID. The decision is driven by the same three tests used in the Chinese memo: whether free cash flow is repeatable, whether the balance sheet provides a real safety cushion, and whether price is low enough against the base and conservative fair-value anchors.

At CNY 54.62, the stock trades at 3.31x the base fair value of CNY 16.48 and at 3.49x the conservative fair value of CNY 15.65. The action is Avoid because quality evidence or valuation support is not sufficient for a purchase discipline, with a quality score of 64/100 and a base-case price-to-FV ratio of 3.31. The report does not treat a high quality score as sufficient by itself; price, evidence depth, and FCF durability must all remain aligned.

Business Breakdown

Business / product / region	2021 revenue	2022 revenue	2023 revenue	2024 revenue	2025 revenue	Five-year change	Latest gross margin / segment profit	Read-through
Consolidated operating revenue	CNY 25.91bn	CNY 21.28bn	CNY 22.82bn	CNY 27.98bn	CNY 31.63bn	5.1%	not disclosed	The five-year revenue trend is used to judge demand resilience and the valuation multiple.

The value driver is the five-year revenue CAGR of 5.1% and latest annual FCF of CNY 8.27bn. These two inputs shape both the quality score and the FCF multiple range. Quantified management outlook was not available from the structured source in this run, so formal follow-up should continue to verify annual reports, earnings calls, and company IR disclosures.

Quality Score

Dimension	Score	Evidence	Deductions / limits
Business model quality	7/10	Revenue, net income, and FCF are all available for cross-checking the innovative and generic drugs profit model.	Formal segment disclosure still needs to be verified.
Moat	13/20	Multi-year scale, profitability, and cash flow indicate customer, channel, brand, or ecosystem advantages.	Competition, regulation, or cycle changes can still compress the multiple.
Cash flow	14/20	Five-year FCF/net income is 0.81 and OCF/net income is 1.19.	Working-capital and capex swings can change normalized FCF.
Capital returns	11/15	Five-year average ROE is 13.0% and average ROIC is 11.4%.	ROIC depends on reliable reconstruction of invested capital.
Balance sheet	10/10	Latest cash is CNY 40.96bn and debt is CNY 74.23m.	The composition of financial assets must be checked in annual reports.
Growth quality	8/10	Revenue CAGR is 5.1%; the FCF trend remains the main cross-check.	A high-growth business cannot be upgraded if valuation has already capitalized it.
Management and accounting	10.1/15	Management and accounting are scored from ownership alignment, capital allocation, dilution, accounting quality, and governance.	The score remains capped by disclosure depth and future follow-up evidence.

The score keeps the company in the investable research universe when it is above 65 and treats scores above 80 as strong quality evidence. A higher score is still constrained by disclosure depth, segment detail, valuation safety, and the need to validate management and accounting items over time.

Management And Accounting

Sub-item	Weight	Score	Evidence	Judgment
Shareholder alignment	20	13/20	Control, board structure, and shareholder returns must be verified through formal disclosures.	Watch
Capital allocation	25	17/25	FCF, cash, debt, and shareholder returns are reviewed together to test reinvestment discipline.	Watch
Incentives and dilution	20	13/20	Equity incentives and dilution need to be rechecked in annual reports and announcements.	Watch
Accounting quality	20	13/20	The match between earnings and FCF is the core evidence in this run.	Watch
Governance and related-party transactions	15	10/15	Audit opinions, related-party activity, and segment disclosure require continued tracking.	Watch
Total	100	67/100	Subtotal converted into the total quality score.	Evidence depth limits a higher score.

Management and accounting are not used as a narrative overlay. They feed directly into the total score through ownership alignment, capital allocation, incentive dilution, accounting quality, governance, and related-party review.

Financial Audit

The valuation uses the five full fiscal years shown below. Quotation currency is CNY; financial currency is CNY; the FX conversion used by the Chinese source is 1.0000 when the currencies match. The risk-free-rate date is 2026-08-07. ROIC is marked not disclosed where invested capital cannot be reconstructed reliably from structured fields.

Year	Revenue	Net income	OCF	Capex	FCF	ROE	ROIC	FCF/revenue	FCF/net income
2025	CNY 31.63bn	CNY 7.71bn	CNY 11.24bn	CNY 2.96bn	CNY 8.27bn	14.3%	12.9%	26.2%	1.07
2024	CNY 27.98bn	CNY 6.34bn	CNY 7.42bn	CNY 1.97bn	CNY 5.45bn	14.7%	13.1%	19.5%	0.86
2023	CNY 22.82bn	CNY 4.30bn	CNY 7.64bn	CNY 1.48bn	CNY 6.16bn	11.0%	9.4%	27.0%	1.43
2022	CNY 21.28bn	CNY 3.91bn	CNY 1.27bn	CNY 1.99bn	CNY -0.73bn	10.9%	9.1%	-3.4%	-0.19
2021	CNY 25.91bn	CNY 4.53bn	CNY 4.22bn	CNY 1.66bn	CNY 2.55bn	14.0%	12.4%	9.9%	0.56

For 2025, revenue was CNY 31.63bn, net income was CNY 7.71bn, OCF was CNY 11.24bn, capex was CNY 2.96bn, and FCF was CNY 8.27bn. The five-year FCF/net-income ratio is 0.81 and OCF/net-income ratio is 1.19. If goodwill, receivables, or financial-asset composition changes materially, formal filings should be reviewed before raising the valuation multiple.

Balance Sheet Summary

Year	Cash and equivalents	Current financial assets	Non-current financial assets	Total debt	Net cash / net debt
2025	CNY 40.96bn	CNY 0.55bn	CNY 1.47bn	CNY 74.23m	CNY 40.88bn
2024	CNY 24.82bn	CNY 0.44bn	CNY 1.07bn	CNY 0.11bn	CNY 24.71bn
2023	CNY 20.75bn	CNY 0.33bn	CNY 0.76bn	CNY 75.18m	CNY 20.67bn
2022	CNY 15.11bn	CNY 0.65bn	CNY 0.74bn	CNY 1.36bn	CNY 13.75bn
2021	CNY 13.63bn	CNY 0.55bn	CNY 0.81bn	CNY 0.15bn	CNY 13.48bn

The balance-sheet read-through is part of the equity value bridge, not an afterthought. Cash and financial assets are discounted before being added to equity value, and debt or senior claims are deducted before common-share value is calculated.

Shareholder Returns

Metric	Latest year	Five-year observation	Judgment
Dividend yield	not disclosed	Needs verification through dividend announcements and annual reports.	Not used as an FV uplift.
Dividend payout ratio	not disclosed	Needs verification through dividend announcements and annual reports.	Cannot replace FCF valuation.
Dividends / FCF	not disclosed	Needs verification through dividend announcements and annual reports.	Prevents a high-dividend value trap.
Buybacks and dilution	not disclosed	Needs verification through dividend announcements and annual reports.	Watch whether per-share value improves.

Dividends, payout ratios, dividends-to-FCF, buybacks, and dilution are used only as capital-allocation cross-checks. They are not double-counted in fair value.

Valuation

The risk-free rate is the CNY government-bond anchor used in the Chinese source, dated 2026-08-07. The method is normalized FCF first, with sustainable growth, a 10% required return, and a quality discount determining the multiple. Cash, financial assets, debt, dilution, and other senior claims are then adjusted separately.

Current baseline: current price CNY 54.62, market cap from the source table, estimated shares from the source table, valuation currency CNY, quotation currency CNY, and FX conversion 1.0000 when applicable.

Scenario	Core assumption	Multiple basis	Fair market value	Fair value per share	Current price / FV	Weight	Next verification
Conservative	Normalized FCF of CNY 8.27bn with a larger discount.	g 2.0%, 8.0x, quality and cyclicality discount	CNY 103.85bn	CNY 15.65	3.49	30%	Whether FCF is sustained.
Base	The five-year FCF base and latest operating state continue.	g 4.0%, 8.7x, discounted by quality score	CNY 109.36bn	CNY 16.48	3.31	50%	Revenue and ROIC trends.
Upside	The five-year FCF base and latest operating state continue.	g 5.0%, 12.0x, capped by the 20x discipline	CNY 136.69bn	CNY 20.59	2.65	20%	Competition and capital allocation improve.

Anchor checks are unchanged from the Chinese memo. The FCF method is the primary anchor; the base-case price-to-FV ratio is 3.31 and does not automatically satisfy a 2x discipline. The profit anchor checks whether five-year average net income points in the same direction as the FCF anchor. Reverse DCF is used to understand the growth and cash-flow durability implied by the current price. Balance-sheet adjustments are applied in common-equity order, and shareholder returns are only a capital-allocation cross-check.

Balance Sheet Adjustment

Item	Book value	Recognition ratio	Value included	Reason
Cash and equivalents	CNY 40.96bn	90%	CNY 36.86bn	Conservative recognition of available cash.
Current financial assets	CNY 0.55bn	65%	CNY 0.36bn	Discounted until the composition is fully disclosed.
Current financial assets	CNY 1.47bn	35%	CNY 0.52bn	Discounted until the composition is fully disclosed.
Borrowings, notes, leases, and senior claims	CNY 74.23m	-100%	CNY -74.23m	Claims ranking ahead of common equity.
Minorities, deferred tax, dilution, or contingencies	CNY 0.00bn	0%	CNY 0.00bn	No material quantifiable deduction in this run.
Total			CNY 37.66bn	Total balance-sheet adjustment.

Buy Discipline And Monitoring

Item	Conclusion
Current action	Avoid; evidence or valuation support is insufficient for a purchase.
Buy condition	Current price/base FV must fall below 0.70, the quality score must remain at least 75, and the mispricing evidence must become stronger.
2x condition	The current price/base FV ratio is 3.31; conservative FV still needs to be verified.
Tracking focus	Revenue trend, FCF/net income, ROIC, net cash/net debt, dividends, buybacks, and governance disclosure.

The monitoring discipline is deliberately mechanical: do not upgrade the signal unless price, quality, mispricing evidence, FCF conversion, ROIC, net cash or net debt, shareholder returns, buybacks, and governance disclosure all continue to support the same conclusion.

Risks To Track

Risk	Judgment	Impact on valuation or signal
FCF quality	Watch	If FCF cannot repeat, the base multiple and buy threshold must be reduced.
Balance sheet	Pass	Higher debt or a deeper discount on financial assets would reduce FV.
Accounting and governance	Watch	Related-party transactions, incentive dilution, or abnormal gains would reduce the management/accounting score.
Shareholder returns	Watch	Dividend-to-FCF coverage and repurchase prices determine capital-allocation quality.

Re-rating Triggers

Trigger	Meaning
FCF/net income below 0.60 for two consecutive reporting periods	Normalized FCF and the quality score need to be cut.
Net debt expands materially or financial assets suffer a large impairment	Balance-sheet adjustments and conservative FV need to be lowered.
Dividends, buybacks, or incentives dilute common-share value materially	The management/accounting score and final signal need to be downgraded.

These triggers are binding monitoring rules. Two consecutive weak FCF conversion periods, a material deterioration in net debt or financial assets, or capital-allocation actions that dilute common-share value all require a lower quality score, lower FV, or a weaker final signal.

Research note: This report is for personal research only and is not personalized investment advice.

Sources

Use	Source	Date	URL
Financial and market data	Public quotation and financial-data platform	2026-08-08	https://quote.eastmoney.com/
Annual reports, filings, dividends, buybacks, governance, incentives, and risk disclosures	Official disclosure portal or company IR	2026-08-08	https://www.sse.com.cn/disclosure/listedinfo/regular/
Risk-free rate	ChinaBond government-bond yield curve	2026-08-07	https://yield.chinabond.com.cn/cbweb-mn/yield_main?locale=zh_CN
Currency conversion or same-currency cross-check	Public FX quotation or same-currency not applicable	2026-08-08	https://quote.eastmoney.com/